Establishment Labs Holdings Inc. (NASDAQ: ESTA), an international medical technology firm committed to enhancing women’s health and wellness, has announced that it has commercially launched its revolutionary product, Motiva Implants, in China. As a leading pioneer in the fields of breast aesthetics and reconstruction, Establishment Labs continues to break new ground with its innovative medical technology.
China, recognized as the second largest market worldwide, is poised to become an even more significant player on the global stage. Juan José Chacón-Quirós, the Founder and Chief Executive Officer of Establishment Labs, enthusiastically noted, China has the opportunity to be much larger.
Ever since its inception, the primary of Establishment Labs has been to revolutionize the realm of medical technology. The introduction of Motiva Implants in China is a testament to their sustained commitment to this overarching goal.
Expansion into the Chinese market has been strategically planned, with the groundwork laid through successfully gaining National Medical Products Administration (NMPA) approval in China for Motiva Implants. This approval has thus signaled Establishment Labs’ entry into one of the most vibrant and dynamic markets for breast aesthetics globally.
Receiving approval in China fortifies our position in the second largest and most dynamic global market for breast aesthetics. We are excited to introduce Motiva Implants and establish a strong presence here, said CEO Chacón-Quirós.
Indeed, the commercial launch of Motiva Implants is a significant milestone for Establishment Labs, and one that could potentially redefine women’s health and wellness across China.
With groundbreaking medical technology and an unwavering commitment to improving women’s health, Establishment Labs is well-poised to make remarkable strides in China with its avant-garde Motiva Implants. This launch not only signifies the company’s expansion in a global context but also stands as a testament to its overarching mission to lead and innovate in the highly competitive field of medical technology.
Comments